Article
Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) - 1 Jan 2000
Ribas Antoni, Glaspy John A, Lee Yohan, Dissette Vivian B, Seja Elisabeth, Vu Huong T, Tchekmedyian N Simon, Oseguera Denise, Comin-Anduix Begonya, Wargo Jennifer A, Amarnani Saral N, McBride William H, Economou James S, Butterfield Lisa H
Abstract excerpt
MART-1(27-35)-peptide-pulsed immature dendritic cells (DCs) resulted in immunologic and clinical activity in a prior phase 1 trial. A phase 2 cohort expansion was initiated to further characterize the phenotype and cytokine milieu of the DC vaccines and their immunologic activity in vitro and to further examine a possible link between clinical activity and determinant spreading. In an open-label phase 2 trial,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.